1.Bejeweled: Chronic bullous disease of childhood in a 2-year old treated with colchicine: A case report.
Danielle Nicolle Dionisio Mejia ; Mae Ramirez-Quizon
Journal of the Philippine Medical Association 2019;97(2):47-51
Linear IgA bullous dermatosis, also known as chronic bullous disease of childhood when present in the pediatric
age group, is a rare blistering disease more predominantly seen in females less than five years old. This case describes a 2-year old girl who presented with scattered, tense vesicles and bullae on an erythematous base forming
the classic “cluster of jewels” appearance. This clinical picture is often mistaken as bullous impetigo, commonly
seen in children, delaying diagnosis and prompt treatment. Histopathologic examination showed subepidermal
blistering with a predominantly neutrophilic inflammatory infiltrate. The direct immunofluorescence studies revealed a linear band of IgA deposition in the basement membrane zone consistent with the diagnosis of CBDC.
The patient was started on colchicine and oral prednisone at 1 mg/kg/day and complete resolution was achieved
within two weeks of therapy.
Colchicine
2.Colchicine in the Treatmint of Dupuytren's Contracture.
Young Ho LEE ; Seong Jae CHOI ; Jong Dae JI ; Gwan Gyu SONG
The Journal of the Korean Rheumatism Association 1998;5(2):205-210
No abstract available.
Colchicine*
;
Dupuytren Contracture*
3.A case of Behcet's syndrome treated by colchicine.
Kwang Yul LEE ; Hyun Chul SHIN ; Min Kwan KIM ; Dong Han BAE
Korean Journal of Obstetrics and Gynecology 1993;36(11):3820-3824
No abstract available.
Behcet Syndrome*
;
Colchicine*
4.Not Available.
Yong ming AN ; Hui jie HUANG ; Zhi wei ZHANG
Journal of Forensic Medicine 2021;37(5):729-731
5.A Fatal Case of Colchicine Poisoning.
Journal of The Korean Society of Clinical Toxicology 2017;15(1):51-55
Colchicine is a drug that has long been used to treat a variety of illnesses; however, it reportedly has adverse effects at apparent toxic doses as well as at lower and therapeutically recommended doses. The typical therapeutic dose of colchicine is up to 2.4 mg daily, although it is sometimes as high as 8–10 mg daily. Here, we describe a case in which the patient showed sudden deterioration and died because of unintentional colchicine poisoning with a relatively small dose. When a colchicine poisoned patient visits the hospital, the physician should identify the patient's colchicine poisoning dose and concomitant drugs. Moreover, the patients should be monitored intensively for 24 to 72 hours and managed with various supportive treatment methods early and actively.
Cardiotoxicity
;
Colchicine*
;
Humans
;
Poisoning*
;
Sepsis
6.A case of Sneddon-Wilkinson disease with hypersensitivity to dapsone successfully managed with colchicine
Jarische Frances S. Lao-Ang ; Ma. Lourdes Nebrida-Idea ; Ma. Lorna F. Frez
Journal of the Philippine Dermatological Society 2019;28(2):58-63
Introduction:
Sneddon-Wilkinson disease (SWD) is a rare, recurrent neutrophilic dermatosis presenting as sterile
pustules, with a predilection for flexural and intertriginous areas.
Case summary:
A 49-year-old Filipino female presented with a three-year history of recurrent pustules and papules
on the flexural areas of trunk and extremities. Skin punch biopsy was done and histopathology was consistent
with subcorneal pustular dermatosis/SWD. She was started on Dapsone but after two weeks of intake, the patient
developed generalized erythematous desquamating plaques on the trunk and extremities, with palmoplantar
involvement. The patient did not have fever, jaundice, lymphadenopathy, and abdominal tenderness. Laboratory
investigation such as complete blood count and liver function tests were normal. The final diagnosis was SWD with
hypersensitivity to Dapsone. Dapsone was immediately discontinued and she was shifted to oral colchicine. After
six weeks of oral colchicine therapy, the lesions have completely resolved. Patient was in remission for six months
thereafter.
Conclusion
SWD is rare and the drug of choice is dapsone. In instances where dapsone is not suitable, oral
colchicine can be an ideal alternative treatment.
Skin Diseases, Vesiculobullous
;
Dapsone
;
Colchicine
7.Death Following Colchicine Poisoning: A Case Report.
Seung Woo KIM ; Sin Deuk LEE ; Tai Ho IM
Journal of the Korean Society of Emergency Medicine 2004;15(6):612-616
Colchicine poisoning is relatively uncommon, but potentially life-threatening, situation confronting the emergency physician. Although the toxic dose of colchicine is reported to be more than 0.5 mg/kg, it is extremely variable. Therefore, the emergency physician should always consider colchicine poisoning to be serious, even when the dose is small. We present a case of death after intentional ingestion of 12 mg (0.17 mg/kg) of colchicine by a 30-year-old male.
Adult
;
Colchicine*
;
Eating
;
Emergencies
;
Humans
;
Male
;
Poisoning*
8.Stabilizing Microtubular Network Facilitates the Intracellular Growth of Orientia tsutsugamushi.
Mee Kyung KIM ; Mi Jeong KIM ; Byung Uk LIM ; Jae Seung KANG
Journal of Bacteriology and Virology 2006;36(2):51-57
Microtubule network provides many intracellular microbes with an efficient way to move within host cells. Orientia tsutsugamushi move from the cell periphery to the microtubule organizing center (MTOC) by dynein-dependent mechanism. In this study, we investigated the role of microtubule on the growth of O. tsutsugamushi. The treatment of infected cells with taxol as well as daunomycin enhanced the bacterial growth in contrast to colchicine. Immunofluorescent (IF) staining of taxol-treated cells exhibited that O. tsutsugamushi clustered tightly near the nucleus with thick bundles of microtubules, whereas dispersed in the cytoplasm in colchicine-treated cells. These results suggest that microtubule network facilitate the growth of O. tsutsugamushi.
Colchicine
;
Cytoplasm
;
Daunorubicin
;
Microtubule-Organizing Center
;
Microtubules
;
Orientia tsutsugamushi*
;
Paclitaxel
9.The Effect of Anticancerous Drug in the Fiboblast-Mediated Collagen Matrix Contraction.
Hyung Woo KWAK ; Chang Soo PARK ; Kyung Hyun JIN ; Jae Myung KIM
Journal of the Korean Ophthalmological Society 1997;38(5):805-816
In vitro PVR(Proliferative vitreoretinopathy) models allow identification of factor which may inhibit porliferation and contraction. In this study we evaluated the contraction of collagen matrix by choroidal fibroblast and the inhibition of contraction by antipoliferative drug. Each antiproliferative drug showed inhibition of collagen matrix contraction : Colchicine (0.1microgram/ml), Cytochalacin (0.05microgram/ml), Puromycin(10microgram/ml). Transmission electron microgram of collagen matrices containing colchicine, cytochalacin or puromycin showed no collagen fiber surrounding choroid fibroblast and showed cell destruction. Scanning electron microgram of collagen matrices containing colchicine, cytochalacin and puromycin showed that collagen fibers were well preserved without distortion. Colchicine, cytochalacin and puromycin are effective inhibitor of cell mediated contraction in additon to it`s potent antiproliferative effect wherease Interfereon has no anticontractile effect. The current study present a model to investigate the effect of antiproliferative drug on fibroblast mediated collagen matrix contraction.
Choroid
;
Colchicine
;
Collagen*
;
Fibroblasts
;
Interferons
;
Puromycin
;
Vitreoretinopathy, Proliferative
10.Colchicine Derivatives Allows Prolonged Survival of Cardiac Allograft in the Rat.
Young Hak KIM ; Hyung Chang LEE ; Won Sang CHUNG ; Jung Ho KANG ; Hyuck KIM ; Sun Ho CHON ; Sung Ho SHINN
The Korean Journal of Thoracic and Cardiovascular Surgery 2005;38(9):595-600
BACKGROUND: Colchicine with its immunosupressive properties has been used with beneficial effects in autoimmune disease, such as Gout, etc. Whether colchicine, by virtue of the above property, could attenuate the process of cardiac allograft rejection in the rats is investigated in this report. MATERIAL AND METHOD: We compared the untreated group (Control, n=6), Cyclosporin A group (10 mg/kg, daily, n=20), and Colchicine derivative group (Colchicine 40 microgram/kg, n=20) of cardiac allografts in the rats. RESULT: In the untreated control group (n=6), all of 6 rats showed rejection within 3 weeks after cardiac allograft. In the cyclosporin A group (n=20), cyclosporin A (10 mg daily oral dose) was administered at a 10 mg daily oral dose and promoted long-term survival (over 100 days). The cyclosporin A group had one mortality at the 18th post-operative day due to infection. Furthermore, in the Colchicine derivatives group (n=20) with a daily IP (Intra Peritoneum) dose (40 ug/kg/day), we observed long-term survival.(>100 days), except for one rat that died of an anesthetic problem (respiratory failure) at the 9th post-operative day. CONCLUSION: Experiments have also been performed to evaluate whether the effect of colchicine derivatives allowed prolonged survival of cardiac allografts compared with the cyclosporin A administration group in the rats.
Allografts*
;
Animals
;
Autoimmune Diseases
;
Colchicine*
;
Cyclosporine
;
Gout
;
Mortality
;
Rats*
;
Virtues